Claims
- 1. recombinant virus encoding a 25 kDa sexual stage surface protein, Pfs25 of Plasmodium falciparum.
- 2. A recombinant virus encoding at least amino acids of Plasmodium falciparum Pfs25.
- 3. The recombinant virus according to claim 1 which is an alpha virus, cowpox virus, canarypox virus, adenovirus, vaccinia virus or animal virus.
- 4. The recombinant virus according to claim 3 which is a vaccinia virus.
- 5. A host cell infected with said recombinant virus according to claim 1 under condition such that said cell expresses said Pfs25 on its surface.
- 6. A transmission blocking vaccine against malaria comprising a recombinant virus encoding Pfs25 of Plasmodium falciparum, in an amount sufficient to induce transmission blocking activity, and a pharmaceutically acceptable carrier.
- 7. A transmission blocking vaccine against malaria comprising a recombinant virus encoding at least 6 amino acids of Plasmodium faciparum Pfs25, in an amount sufficient to induce transmission blocking activity, and a pharmaceutically acceptable carrier.
- 8. The vaccine according to claim 6 which further comprises a protective malarial antigen.
- 9. The vaccine according to claim 6 wherein said is an alpha virus, cowpox virus, canarypox virus, adenovirus, vaccinia virus or animal virus.
- 10. The vaccine according to claim 6 wherein said virus is a vaccinia virus.
- 11. The vaccine according to claim 6 which further comprises an adjuvant.
- 12. A transmission blocking vaccine against malaria comprising Pfs25 protein purified from said host cell according to claim 5, in an amount sufficient to induce transmission blocking activity, and a pharmaceutically acceptable carrier.
- 13. The vaccine according to claim 12 which further comprises an adjuvant.
- 14. A transmission blocking vaccine against malaria comprising a Pfs25 peptide at least 6 amino acids in length, purified from a host cell infected with the recombinant virus according to claim 2, in a amount sufficient to induce transmission blocking activity, and a pharmaceutically acceptable carrier.
- 15. The vaccine according to claim 14 which further comprises a protective malarial antigen.
- 16. A method of preventing transmission of malarial infection comprising administering to a patient a recombinant virus encoding Pfs25 of Plasmodium falciparum, in an amount sufficient to induce transmission blocking activity.
- 17. A method of preventing transmission of malarial infection comprising administering to a patient the recombinant virus according to claim 2, in an amount sufficient to induce transmission blocking activity.
- 18. The method according to claim 16 further comprising administering to said patient, a second time, the recombinant virus, in an amount sufficient to boost said patient's immunity to said disease.
- 19. The method according to claim 16 further comprising administering to said patient Pfs25 protein purified from a recombinant expression system in an amount sufficient to boost said patient's transmission blocking activity.
- 20. The method according to claim 19 wherein said recombinant expression system is a host cell infected with a recombinant virus encoding a 25 kDa sexual stage surface protein, Pfs25 of Plasmodium falciparum.
- 21. A method of preventing transmission of malarial infection comprising administering to a patient Pfs25 protein purified from said host cell according to claim 5, in an amount sufficient to induce transmission blocking activity.
- 22. The method according to claim 21 further comprising administering to said patient a recombinant virus encoding Pfs25 of Plasmodium falciparum, in an amount sufficient to boost said patient's transmission blocking activity.
- 23. The method according to claim 21 further comprising administering to said patient, a second time, Pfs25 protein purified from a recombinant expression system, in an amount sufficient to boost said patient's transmission blocking activity.
- 24. The method according to claim 23 wherein said recombinant expression system is a host cell infected with a recombinant virus encoding a 25 kDa sexual stage surface protein, Pfs25 of Plasmodium falciparum.
Parent Case Info
[0001] The present application is a continuation-in-part application of the Miller et al application Ser. No. 07/188,918 filed May 2, 1988, the entire contents of which are hereby incorporated by reference.
Continuations (3)
|
Number |
Date |
Country |
Parent |
08110457 |
Aug 1993 |
US |
Child |
08400421 |
Mar 1995 |
US |
Parent |
07908765 |
Jul 1992 |
US |
Child |
08110457 |
Aug 1993 |
US |
Parent |
07658845 |
Feb 1991 |
US |
Child |
07908765 |
Jul 1992 |
US |